Abiopharma

Nutrien Cautions Investors Regarding Ocehan LLC’s Below Market “Mini-Tender” Offer

Lotus Tech Announces Operational and Earnings Reporting Updates

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

COMP Investors Have Opportunity to Join Compass, Inc. Fraud Investigation with the Schall Law Firm

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

Summit Plc - Current report filing

TAL Education Group Files Its Annual Report on Form 20-F

Bluerock Homes Trust (BHM) Announces Second Quarter Dividends on Common Stock

ETC Announces Fiscal 2026 Full Year and Fourth Quarter Results

Immediate Report of Meeting